1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. DYRK

DYRK

Dual specificity tyrosine phosphorylation regulated kinase; Dual specificity tyrosine regulated kinase

DYRKs (dual-specificity tyrosine-regulated kinases; dual-specificity tyrosine phosphorylation-regulated kinases) comprise a family of protein kinases within the CMGC group of the eukaryotic kinome. DYRKs contain five members in humans that are clustered into two classes based on their phylogenetic relationships: class I DYRKs, DYRK1A and DYRK1B and class II DYRKs, DYRK2, DYRK3, and DYRK4.

DYRK kinases are “dual specificity” kinases, as they can phosphorylate both tyrosine (Y) and serine/threonine (S/T) residues, although Y-phosphorylation is limited to their autophosphorylation activity. DYRK kinases phosphorylate a broad set of substrates that are involved in a wide range of cellular processes, and they are thought to fulfill essential biological functions both during development and in maintaining homeostasis during the adult life. Consequently, the aberrant regulation or expression of DYRK kinases has been associated with several human pathologies, including cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P3992
    5-FAM-Dyrktide
    5-FAM-Dyrktide is a 5-FAM labeled Dyrktide. Dyrktide, a substrate, is efficiently phosphorylated by DYRK1A (Km=35 μM) but not by ERK2.
    5-FAM-Dyrktide
  • HY-125288
    DS42450411
    Inhibitor
    DS42450411 is an orally active hepcidin production inhibitor with an IC50 of 32 nM. DS42450411 strongly inhibits DYRK1a, with an IC50 of 54 nM. DS42450411 does not inhibit ALK2. In an acute inflammatory mouse model induced by IL-6, DS42450411 significantly reduces serum hepcidin levels. DS42450411 can be used for studying iron homeostasis.
    DS42450411
  • HY-144695
    Dyrk1A/α-synuclein-IN-1
    Inhibitor
    Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and α-synuclein aggregation inhibitor with IC50 values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect.
    Dyrk1A/α-synuclein-IN-1
  • HY-125202
    KuWal151
    Inhibitor
    KuWal151 is a CLK1, CLK2 and CLK4 inhibitor with a high selectivity margin towards DYRK kinases. KuWal151 has potent antiproliferative activity in an array of cultured cancer cell lines.
    KuWal151
  • HY-157995
    Dyrk1A-IN-7
    Inhibitor
    Dyrk1a-in-7 (Compound 29) is a selective DYRK1A kinase inhibitor, and has good kinase selectivity for CLK1 kinase. The IC50 value of DYRK1A is 28 nM. For CLK2, Kd is 17.5 nM. Dyrk1a-in-7 can be used in the research of cancer, type Ⅱ diabetes and neurological diseases.
    Dyrk1A-IN-7
  • HY-RS04099
    Dyrk2 Mouse Pre-designed siRNA Set A
    Inhibitor

    Dyrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dyrk2 Mouse Pre-designed siRNA Set A
  • HY-176402
    Dyrk1A-IN-13
    Inhibitor
    Dyrk1A-IN-13 (Compound 1) is a DYRK1A inhibitor (IC50: 41 nM). Dyrk1A-IN-13 reduces LPS-induced NO production and has antioxidant and anti-inflammatory activities. Dyrk1A-IN-13 can be used in the research of Alzheimer's disease, cancer and diabetes.
    Dyrk1A-IN-13
  • HY-139830
    Dyrk1A-IN-1
    Inhibitor
    Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC50 = 119 nM) and the aggregation of tau and α-syn oligomers.
    Dyrk1A-IN-1
  • HY-161014
    DYRK2-IN-1
    Inhibitor
    DYRK2-IN-1 (Compd 54) is an orally bioavailable DYRK2 inhibitor, with an IC50 of 14 nM. DYRK2-IN-1 (Compd 54) can be used in the study of prostate cancer.
    DYRK2-IN-1
  • HY-RS04098
    DYRK2 Human Pre-designed siRNA Set A
    Inhibitor

    DYRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for DYRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DYRK2 Human Pre-designed siRNA Set A
  • HY-175477
    UNC9750
    Inhibitor
    UNC9750 is an inositol phosphate multikinase (IPMK) inhibitor with IC50 values ​​of 31.6 and 374 nM for IPMK and IP6K2, respectively.. UNC9750 inhibits cellular accumulation of InsP5, the direct product of IPMK kinase activity, while having no effect on either InsP6 or InsP7 levels. UNC9750 has ≥ 75% inhibition of four kinases (DAPK1, DYRK1B, PDGFR, and KDR). UNC9750 can be used for the study of glioblastoma.
    UNC9750
  • HY-P3812
    Woodtide
    Woodtide is a substrate for the DYRK (DYRK) family of kinases whose sequence is based on that around the DYRK phosphorylation site in FKHR.
    Woodtide
  • HY-144696
    Dyrk1A/α-synuclein-IN-2
    Inhibitor
    Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC50 of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect.
    Dyrk1A/α-synuclein-IN-2
  • HY-163514
    hAChE-IN-8
    Inhibitor
    hAChE-IN-8 (Compound S-12) is a orally effective and selective inhibitor of hAChE (IC50=0.486 μM). hAChE-IN-8 also inhibits BACE-1 (IC50=0.542 μM), and does not inhibit Dyrk1A (IC50>10 μM). hAChE-IN-8 can reduce Aβ aggregation, has good blood-brain barrier penetration. hAChE-IN-8 is mainly used in Alzheimer's disease research.
    hAChE-IN-8
  • HY-N2892
    Aristolactam A IIIa
    Inhibitor
    Aristolactam A IIIa (Sch 546909) is an aristolactam-type alkaloid that can be isolated from Glycosmis chlorosperma. Aristolactam A IIIa is a DYRK1A Inhibitor. Aristolactam A IIIa inhibits platelet aggregation induced by arachidonic acid (AA), collagen and platelet-activating factor (PAF). Aristolactam A IIIa has strong cytotoxic effect on HeLa cells.
    Aristolactam A IIIa
  • HY-177416
    MU1787
    Inhibitor
    MU1787 (Compound 22h) is a Homeodomain interacting protein kinase (HIPK) inhibitor with IC50s of 285, 123 and 283 nM for HIPK1, HIPK2 and HIPK3, respectively. HIPK have distinct or contradictory effects on cell proliferation and tissue growth.
    MU1787
  • HY-144617
    JH-XIV-68-3
    Inhibitor
    JH-XIV-68-3 is a selective macrocyclic inhibitor of DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines.
    JH-XIV-68-3
  • HY-128759
    DYRKs-IN-2
    Inhibitor
    DYRKs-IN-2 (Example 132) is a potent DYRKs inhibitor with IC50s of 30.6 nM and 12.8 nM for DYRK1B and DYRK1A, respectively. DYRKs-IN-2 has antitumor activity.
    DYRKs-IN-2
  • HY-129449
    AnnH31
    Inhibitor 99.91%
    AnnH31 is a Dyrk1A inhibitor (IC50: 81 nM). AnnH31 also inhibits MAO-A with an IC50 of 3.2 μM. AnnH31 inhibits cell viability of HeLa, PC12 and SH-SY5Y cells.
    AnnH31
  • HY-RS04100
    Dyrk2 Rat Pre-designed siRNA Set A
    Inhibitor

    Dyrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Dyrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Dyrk2 Rat Pre-designed siRNA Set A
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.